Whether it's the ongoing steroids controversy surrounding Major League baseball or another Olympic athlete being banned from competition, the use of illegal steroids and performance-enhancing drugs is clearly on the rise. Because of this, both collegiate and professional sports teams are finding themselves under increasing pressure to monitor the drugs their athletes take.
Skyrocketing gas prices have put a dent in consumers' wallets, but chains and independents are still looking to a rosy holiday. Many expect consumers to flock to neighborhood drugstores and pharmacy Web sites to fill Santa's sleigh with gifts.
The Medicare Modernization Act (MMA) sets a precedent for the design of prescription drug plans (PDPs) by requiring that medication therapy management (MTM) services be offered to certain enrollees. The MMA targets beneficiaries for MTM if they take multiple medications, have multiple chronic diseases, and expect to have total drug costs in excess of $4,000 per year.
The other day, I had a patient who told me, "The doctor won't let me have any more Meridia, and it's your fault."
The Pharmacy Compounding Accreditation Board (PCAB) is gearing up to graduate the first class of pharmacies able to meet tough quality standards to win its seal of approval.
Pertussis, known also as whooping cough, is a highly communicable infectious disease of the respiratory tract caused by airborne exposure to Bordetella pertussis, a gram-negative bacillus. In addition to the coughing and choking spells that make breathing difficult, major complications—most common among infants and young children—include hypoxia, apnea, pneumonia, seizures, encephalopathy, and malnutrition. In a teleconference conducted recently by the National Foundation for Infectious Diseases, several physicians discussed the new adult recommendations for pertussis booster vaccinations.
Opioids decrease pain and improve functioning. But some patients are reluctant to take opioids because they want to "be engaged in life."
Insulin sensitizers are poised to become standard medications to reduce the risk of coronary events in patients with Type 2 diabetes, said researchers at the American Heart Association's Scientific Sessions 2005, held recently in Dallas.
A new treatment option for treating T-cell lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) is on the horizon. In 2006, GlaxoSmithKline will begin marketing the recently approved nelarabine (Arranon), a water-soluble pro-drug of the cytotoxic deoxyguanosine analog 9-?-D-arabinofuranosylguanine (ara-G).
The Food & Drug Administration has approved deferasirox (Exjade, Novartis Pharmaceuticals) for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in adults and children age two and older. "Iron overload is a potentially fatal consequence among patients with sickle cell disease, myelodysplastic syndromes, and thalassemia who regularly receive blood transfusions," said Alice Cohen, M.D., director of the division of hematology and oncology at Newark Beth Israel Medical Center, Newark, N.J. If left untreated, excess iron may lead to significant damage to the heart, liver, and other vital organs.
Don't expect Medicare beneficiaries to qualify for medication therapy management (MTM) until the second or third quarter of 2006. And data on the actual health outcomes of the 2006 program will not be available until late 2007 or 2008. That timeline came from officials at the Centers for Medicare & Medicaid Services, who spoke at an American Health Quality Association (AHQA) meeting in Arlington, Va., last month.
Don't leave the future of pharmacy practice in the hands of others. So urged John Gans, executive VP of APhA, at a recent seminar on drug importation and counterfeiting at the Arnold & Marie Schwartz College of Pharmacy and Health Sciences in New York.
ADA: Florida Medicaid reform threatens diabetics CMS pushes Part D help for lower-income folks Single-day Famvir shortens duration of herpes Nurses again top R.Ph.s in ethics poll Longs, Calif. Blue Shield to market Medicare Part D Pharmacists disagree over morning-after pill bill Survey: Physicians, R.Ph.s disagree on OTC statins Study explains higher risk of hypertension in Blacks LTCPA to CMS: Let's discuss rebate disclosure Novartis issues breast cancer drug warning FDA committee supports safety of Daytrana Amgen warns about Aranesp, Epogen Flomax tied to cataract surgery condition FDA approves simplified Kogenate reconstitution Firm seeks reports of Medicare Rx fraud, abuse British R.Ph.s win independent prescribing Part D Web site inflated some Rx prices
There are many ways to reduce Medicaid costs Studiocom announces new Medicare site at CVS.com PharmaCare No. 1 in PBMI customer satisfaction report FDA announces meeting, seeks comments and data Pharmacist guild, Kaiser reach tentative wage agreement Genelex offering senior discount on lifesaving genetic tests Duane Reade replaces CEO with Longs Drug exec
FDA: Don't worry, Tamiflu is safe to use FDA issues asthma advisory Hormones not needed by most menopausal women Long-term care alliance: End Medicare confusion CVS becomes AARP featured employer Experts agree on vitamin D's role in bone health Coalition: Don't use supplements against avian flu
In a move to expand efforts to control hospital-acquired infections, the Pennsylvania Health Care Cost Containment Council (PHC4) recently awarded grants totaling $150,000 to six state hospitals. The hospitals will use the money to implement projects to reduce the number of surgical-site infections, Foley catheter-associated urinary tract infections, ventilator-associated pneumonia and central line-associated bloodstream infections, and ventriculostomy and/ or medically resistant staphylococcus infections, said PHC4 officials.
In a move to expand efforts to control hospital-acquired infections, the Pennsylvania Health Care Cost Containment Council (PHC4) recently awarded grants totaling $150,000 to six state hospitals. The hospitals will use the money to implement projects to reduce the number of surgical-site infections, Foley catheter-associated urinary tract infections, ventilator-associated pneumonia and central line-associated bloodstream infections, and ventriculostomy and/ or medically resistant staphylococcus infections, said PHC4 officials.
I recently read a book titled, Dangerous Doses: How Counterfeiters Are Contaminating America's Drug Supply (Harcourt, 2005). It is written by Katherine Eban, an investigative medical reporter who provides a very detailed account of the counterfeiting of drugs and other major problems in the U.S. drug distribution system. Most people have little awareness of the scope of these problems or the potential consequences.
DEA proposes hike in fees Novartis recalls three products VA revises co-pay for outpatient drugs E-Rxing initiative requires pharmacy link Baxter to withdraw infusion pump Organon launches DTC campaign for NuvaRing FDA approves dosing change for cholesterol drug Consumer groups file lawsuit over dual eligibles ModernHEALTH acquires BioFusion Euflexxa launched for osteoarthritis knee pain Pharmacies must register to dispense isotretinoin FDA approves new indication for Merck's Invanz King reaches Medicaid settlement Unusual process used in denying OTC Plan B CDC: Provide materials when giving flu shots ASHP urges Medicare patients to choose carefully McKesson shuns secondary Rx sources Drug importation efforts lacking, says GAO California R.Ph.s honor Mayer
The government agency responsible for overseeing the 340B Drug Discount Program again has the power to access data on the drug prices charged to healthcare providers who serve underprivileged communities, following an intervention by Senator Chuck Grassley (R, Iowa).
Having trouble rationalizing the use of popular but off-label critical care agents? A special session at the American College of Clinical Pharmacy's annual meeting explored evidence for the use of vasopressin, Factor VIIa, intravenous proton pump inhibitors, and dexmedetomidine (Precedex, Abbott Laboratories).
An exclusive survey of nurses reveals they hold pharmacists in high regard
Hospitals that make use of ForHealth's IntelliFill i.v. system can now package injectable drugs for prescription compounding in Samson Medical Technologies' SmartPak Reservoir Bags. These are sealed plastic bags in a foil overwrap that can contain up to 300 gm of sterile powder. ForHealth Technologies has reached an agreement with Samson to make this possible.
Supporters of the notion that apologies are better than malpractice lawsuits got a boost in late September. Sens. Hillary Rodham Clinton (D, N.Y.) and Barack Obama (D, Ill.) introduced the National Medical Error Disclosure and Compensation (MEDiC) Act to encourage hospitals to apologize after medical errors and negotiate fair compensation.
A new project in mid-Atlantic region hospitals puts the spotlight on reconciling medications for intensive care unit (ICU) and operating room patients. As part of a nationwide "100,000 Lives and Beyond" Collaborative, pharmacists who care for patients in Delaware, Maryland, Northern Virginia, and Washington, D.C., hospitals beginning in January 2006 will have the opportunity to formalize processes for getting a complete and accurate list of each patient's current home medications, including name, dosage, frequency, and route and comparing them to the physician's admission, transfer, and/or discharge orders.
At Sentara Healthcare in Norfolk, Va., an aggressive program borrowed from the nuclear energy industry recently won the health system a prestigious patient safety award. Called "Culture of Safety," the program focuses on what its practitioners call behavior-based expectations (BBEs), or "Red Rules," emphasizing communication and accountability.
With greater responsibility for the pharmacy profession ought to come greater recognition. That was the message at the 10th annual ASHP Conference for Leaders in Health-System Pharmacy held recently in Chicago.
The fast-paced complex environment of a hospital critical care unit presents significant patient safety challenges for healthcare practitioners. High-risk decisions are often made with incomplete patient data, and, because patients require high-intensity care, if something goes wrong, they have a higher risk of getting hurt.
Deep vein thrombosis (DVT) and pulmonary embolism (PE) are on the way out. Not the conditions, which represent one of the most significant causes of hospital-associated morbidity and mortality, but the names. The familiar terms DVT and PE are being replaced with a broader term, venous thromboembolism, or VTE.
Saying it's an exciting time for the use of medications to treat opioid addiction, the federal Substance Abuse & Mental Health Services Administration (SAMHSA) has released a protocol giving details of the clinical pharmacology, screening, treatment matching, and other aspects of recommended use.